Crystalpharmatech

About Crystalpharmatech

Crystal Pharmatech is a technology-focused contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in solid-state research and formulation development for the pharmaceutical industry. Founded in 2010, the company provides integrated services that include active pharmaceutical ingredient (API) solid-state research, crystallization, preformulation, and formulation development and manufacturing. The company was co-founded by Alex Chen, who serves as CEO.

Crystal Pharmatech operates globally with research and development centers in Suzhou (China), New Jersey, San Francisco (USA), and Toronto (Canada). The company serves a broad client base, including 8 of the top 10 multinational pharmaceutical companies, and has supported over 1,000 clients with more than 2,000 new chemical entities. The business model is centered on providing comprehensive, integrated solutions to de-risk client assets and accelerate molecules to clinical trials. A key offering is the Mol2Med™ First-Time-Right approach, which aims to secure a robust API form and a scalable manufacturing process. The company's services cover the entire drug lifecycle, from preclinical development to commercial manufacturing. Its subsidiary, Crystal Formulation Services (CFS), focuses on oral solid dosage formulation and has received manufacturing licenses from the China National Medical Products Administration (NMPA) as well as GMP and GDP certifications in line with World Health Organization standards.

The company's core services are centered on material science and crystallization engineering. This includes solid form screening for polymorphs, salts, and cocrystals, as well as crystallization process development. Crystal Pharmatech utilizes advanced technologies for solid-state characterization, such as XRPD, DSC, TGA, and solid-state NMR. Its formulation capabilities are extensive, covering conventional tablets, pediatric mini-tablets, and enabling technologies like spray drying and hot melt extrusion for poorly soluble compounds. The scientific leadership team possesses an average of 20 years of experience, having delivered over 100 early-phase and multiple commercialized products.